Boehringer breathes easier as TIOSPIR 'confirms Respimat safety'
This article was originally published in Scrip
Boehringer Ingelheim has presented the results of the TIOSPIR (Tiotropium Safety and Performance in Respimat) study which demonstrate the non-inferiority of tiotropium delivered as a mist via the Respimat inhaler compared to the older Spiriva HandiHaler (tiotropium powder) on all-cause mortality outcomes in COPD patients.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.